XML 40 R30.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SEGMENT AND ENTERPRISE-WIDE INFORMATION (Tables)
 9 Months Ended
Dec. 28, 2019
Segment Reporting [Abstract]  
Selected Information by Business Segment
Selected information by reportable segment is presented below:
 
Three Months Ended
 
Nine Months Ended
(In thousands)
December 28,
2019
 
December 29,
2018
 
December 28,
2019
 
December 29,
2018
Net revenues
 
 
 
 
 
 
 
Plasma
$
120,997

 
$
112,738

 
$
348,141

 
$
318,878

Blood Center
85,314

 
84,775

 
246,977

 
248,106

Hospital
50,753

 
47,410

 
147,602

 
140,686

Net revenues by business unit
257,064

 
244,923

 
742,720


707,670

Service (1)
5,197

 
4,875

 
15,339

 
13,937

Effect of exchange rates
(3,291
)
 
(2,442
)
 
(8,072
)
 
(3,323
)
Net revenues
$
258,970

 
$
247,356

 
$
749,987

 
$
718,284

(1) Reflects revenue for service, maintenance and parts
 
 
 
 
 
Three Months Ended
 
Nine Months Ended
(In thousands)
December 28,
2019
 
December 29,
2018
 
December 28,
2019
 
December 29,
2018
Segment operating income
 
 
 
 
 
 
 
Plasma
$
59,343

 
$
47,133

 
$
169,844

 
$
133,661

Blood Center
42,197

 
41,478

 
121,124

 
121,005

Hospital
20,593

 
18,163

 
60,360

 
56,006

Segment operating income
122,133

 
106,774

 
351,328

 
310,672

  Corporate expenses (1)
(63,080
)
 
(66,229
)
 
(188,363
)
 
(196,178
)
  Effect of exchange rates
2,521

 
2,133

 
7,791

 
7,782

Impairment of assets and other related charges
—

 
—

 
(51,220
)
 
(21,170
)
Deal amortization
(5,772
)
 
(6,131
)
 
(17,681
)
 
(18,667
)
PCS2 accelerated depreciation and related costs
(6,649
)
 
(4,822
)
 
(18,708
)
 
(13,203
)
Gain on sale of assets
—

 
—

 
8,083

 
—

Restructuring and turnaround costs
(7,798
)
 
(1,791
)
 
(13,582
)
 
(7,258
)
European Medical Device Regulation costs
(448
)
 
—

 
(1,005
)
 
—

Legal Charges
—

 
(1,614
)
 
701

 
(2,289
)
Operating income
$
40,907

 
$
28,320

 
$
77,344

 
$
59,689

(1) Reflects shared service expenses including quality and regulatory, customer and field service, research and development, manufacturing and supply chain, as well as other corporate support functions.
Schedule of Revenues by Product Line and Geographic Regions

Management reviews revenue based on the reportable segments noted above. Although these reportable segments are primarily product-based, they differ from the Company’s product line revenues for Plasma products and services and Blood Center products and services. Specifically, the Blood Center reportable segment includes plasma products utilized for collection in blood centers primarily for transfusion purposes. Additionally, product line revenues also include service revenues which are excluded from the reportable segments.

Net revenues by product line are as follows:
 
Three Months Ended
 
Nine Months Ended
(In thousands)
December 28,
2019
 
December 29,
2018
 
December 28,
2019
 
December 29,
2018
Plasma products and services
$
141,231

 
$
131,823

 
$
406,825

 
$
373,078

Blood Center products and services
66,126

 
67,155

 
191,648

 
199,881

Hospital products and services
51,613

 
48,378

 
151,514

 
145,325

Net revenues
$
258,970

 
$
247,356

 
$
749,987

 
$
718,284

Net revenues generated in the Company's principle operating regions on a reported basis are as follows:
 
Three Months Ended
 
Nine Months Ended
(In thousands)
December 28,
2019
 
December 29,
2018
 
December 28,
2019
 
December 29,
2018
United States
$
167,238

 
$
157,457

 
$
485,493

 
$
452,523

Japan
19,268

 
17,734

 
55,111

 
52,295

Europe
40,984

 
40,977

 
115,811

 
119,075

Asia
29,436

 
29,166

 
88,269

 
89,136

Other
2,044

 
2,022

 
5,303

 
5,255

Net revenues
$
258,970

 
$
247,356

 
$
749,987

 
$
718,284